Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 17/20 | 0.70 |
| ▸ | DYRK1A | Q13627 | 17/20 | 0.70 |
| ▸ | WNT1 | P04628 | 6/20 | 0.70 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.66 |
| ▸ | ABL1 | P00519 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25602322 | 1.00 | GSK3B (0.70) | GSK3BDYRK1AWNT1MKNK1ABL1 | |
| SCHEMBL25602324 | 0.90 | DYRK1A (0.56) | GSK3BDYRK1AWNT1MKNK1ABL1 | |
| SCHEMBL31165742 | 0.90 | DYRK1A (0.56) | GSK3BDYRK1AWNT1MKNK1ABL1 | |
| SCHEMBL25611765 | 0.89 | DYRK1A (0.74) | GSK3BDYRK1AWNT1MKNK1ABL1 | |
| SCHEMBL25612077 | 0.89 | GSK3B (0.56) | GSK3BDYRK1AWNT1MKNK1ABL1 | |
| SCHEMBL25602457 | 0.88 | GSK3B (0.61) | GSK3BDYRK1AWNT1MKNK1 | |
| SCHEMBL25611174 | 0.88 | DYRK1A (0.55) | GSK3BDYRK1AWNT1MKNK1ABL1 | |
| SCHEMBL31501380 | 0.88 | GSK3B (0.61) | GSK3BDYRK1AWNT1MKNK1 | |
| SCHEMBL31501360 | 0.87 | MKNK1 (0.64) | GSK3BDYRK1AWNT1MKNK1ABL1 | |
| SCHEMBL25602730 | 0.87 | MKNK1 (0.64) | GSK3BDYRK1AWNT1MKNK1ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250066318-A1 | HETEROCYCLIC COMPOUNDS AS DYRK1A INHIBITORS | PROTHENA BIOSCIENCES INC | 2025-02-27 | — | — | US | disclosed |
| CN-118843626-A | Heterocyclic compounds as DYRK1A inhibitors | 普罗塞纳生物科学有限公司 | 2024-10-25 | — | — | CN | disclosed |
| EP-4444421-A2 | HETEROCYCLIC COMPOUNDS AS DYRK1A INHIBITORS | Prothena Biosciences Limited (IE) | 2024-10-16 | — | — | EP | disclosed |
| WO-2023107714-A2 | METHODS FOR TREATING NEUROLOGICAL DISORDERS | PROTHENA BIOSCIENCES LIMITED (IE) | 2023-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250066318-A1 | HETEROCYCLIC COMPOUNDS AS DYRK1A INHIBITORS | DYRK1A, DYRK2, DYRK1B | GSK3B 121/4885DYRK1A 1/4885WNT1 1152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.